Considering the origin of ARPE19 and IMR90, regulation of the immune response by SMARCB1 may be relevant and better observed than in other cells of other origins, but we believe that this phenomenon can be expanded in other contexts, especially SMARCB1-dysregulated cells, such as those in cancers. Here, SMARCB1 is linked to cancer.